Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.
Identifieur interne : 001404 ( PubMed/Checkpoint ); précédent : 001403; suivant : 001405Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.
Auteurs : Thi Thanh Hanh Nguyen [Corée du Sud] ; Hwa-Ja Ryu ; Se-Hoon Lee ; Soonwook Hwang ; Vincent Breton ; Joon Haeng Rhee ; Doman KimSource :
- Bioorganic & medicinal chemistry letters [ 1464-3405 ] ; 2011.
Descripteurs français
- KwdFr :
- Activation enzymatique (), Bibliothèques de petites molécules, Concentration inhibitrice 50, Cysteine endopeptidases (génétique), Escherichia coli (génétique), Escherichia coli (métabolisme), Fixation compétitive, Inhibiteurs de protéases (), Inhibiteurs de protéases (pharmacologie), Modèles moléculaires, Protéines recombinantes (), Protéines recombinantes (génétique), Protéines virales (antagonistes et inhibiteurs), Protéines virales (génétique), Simulation numérique, Structure moléculaire, Systèmes de délivrance de médicaments, Virus du SRAS (), Virus du SRAS (enzymologie).
- MESH :
- antagonistes et inhibiteurs : Protéines virales.
- enzymologie : Virus du SRAS.
- génétique : Cysteine endopeptidases, Escherichia coli, Protéines recombinantes, Protéines virales.
- métabolisme : Escherichia coli.
- pharmacologie : Inhibiteurs de protéases.
- Activation enzymatique, Bibliothèques de petites molécules, Concentration inhibitrice 50, Fixation compétitive, Inhibiteurs de protéases, Modèles moléculaires, Protéines recombinantes, Simulation numérique, Structure moléculaire, Systèmes de délivrance de médicaments, Virus du SRAS.
English descriptors
- KwdEn :
- Binding, Competitive, Computer Simulation, Cysteine Endopeptidases (genetics), Drug Delivery Systems, Enzyme Activation (drug effects), Escherichia coli (genetics), Escherichia coli (metabolism), Inhibitory Concentration 50, Models, Molecular, Molecular Structure, Protease Inhibitors (chemistry), Protease Inhibitors (pharmacology), Recombinant Proteins (chemistry), Recombinant Proteins (genetics), SARS Virus (drug effects), SARS Virus (enzymology), Small Molecule Libraries, Viral Proteins (antagonists & inhibitors), Viral Proteins (genetics).
- MESH :
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemistry : Protease Inhibitors, Recombinant Proteins.
- chemical , genetics : Cysteine Endopeptidases, Recombinant Proteins, Viral Proteins.
- drug effects : Enzyme Activation, SARS Virus.
- enzymology : SARS Virus.
- genetics : Escherichia coli.
- metabolism : Escherichia coli.
- chemical , pharmacology : Protease Inhibitors.
- Binding, Competitive, Computer Simulation, Drug Delivery Systems, Inhibitory Concentration 50, Models, Molecular, Molecular Structure, Small Molecule Libraries.
Abstract
The 3C-like protease (3CL(pro)) of severe acute respiratory syndrome associated coronavirus (SARS-CoV) is vital for SARS-CoV replication and is a promising drug target. Structure based virtual screening of 308307 chemical compounds was performed using the computation tool Autodock 3.0.5 on a WISDOM Production Environment. The top 1468 ranked compounds with free binding energy ranging from -14.0 to -17.09 kcal mol(-1) were selected to check the hydrogen bond interaction with amino acid residues in the active site of 3CL(pro). Fifty-three compounds from 35 main groups were tested in an in vitro assay for inhibition of 3CL(pro) expressed by Escherichia coli. Seven of the 53 compounds were selected; their IC(50) ranged from 38.57±2.41 to 101.38±3.27 μM. Two strong 3CL(pro) inhibitors were further identified as competitive inhibitors of 3CL(pro) with K(i) values of 9.11±1.6 and 9.93±0.44 μM. Hydrophobic and hydrogen bond interactions of compound with amino acid residues in the active site of 3CL(pro) were also identified.
DOI: 10.1016/j.bmcl.2011.03.034
PubMed: 21470860
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:21470860Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.</title><author><name sortKey="Nguyen, Thi Thanh Hanh" sort="Nguyen, Thi Thanh Hanh" uniqKey="Nguyen T" first="Thi Thanh Hanh" last="Nguyen">Thi Thanh Hanh Nguyen</name><affiliation wicri:level="1"><nlm:affiliation>School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>School of Biological Sciences and Technology, Chonnam National University, Gwangju</wicri:regionArea><wicri:noRegion>Gwangju</wicri:noRegion></affiliation></author><author><name sortKey="Ryu, Hwa Ja" sort="Ryu, Hwa Ja" uniqKey="Ryu H" first="Hwa-Ja" last="Ryu">Hwa-Ja Ryu</name></author><author><name sortKey="Lee, Se Hoon" sort="Lee, Se Hoon" uniqKey="Lee S" first="Se-Hoon" last="Lee">Se-Hoon Lee</name></author><author><name sortKey="Hwang, Soonwook" sort="Hwang, Soonwook" uniqKey="Hwang S" first="Soonwook" last="Hwang">Soonwook Hwang</name></author><author><name sortKey="Breton, Vincent" sort="Breton, Vincent" uniqKey="Breton V" first="Vincent" last="Breton">Vincent Breton</name></author><author><name sortKey="Rhee, Joon Haeng" sort="Rhee, Joon Haeng" uniqKey="Rhee J" first="Joon Haeng" last="Rhee">Joon Haeng Rhee</name></author><author><name sortKey="Kim, Doman" sort="Kim, Doman" uniqKey="Kim D" first="Doman" last="Kim">Doman Kim</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21470860</idno><idno type="pmid">21470860</idno><idno type="doi">10.1016/j.bmcl.2011.03.034</idno><idno type="wicri:Area/PubMed/Corpus">001526</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001526</idno><idno type="wicri:Area/PubMed/Curation">001526</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001526</idno><idno type="wicri:Area/PubMed/Checkpoint">001404</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001404</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.</title><author><name sortKey="Nguyen, Thi Thanh Hanh" sort="Nguyen, Thi Thanh Hanh" uniqKey="Nguyen T" first="Thi Thanh Hanh" last="Nguyen">Thi Thanh Hanh Nguyen</name><affiliation wicri:level="1"><nlm:affiliation>School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>School of Biological Sciences and Technology, Chonnam National University, Gwangju</wicri:regionArea><wicri:noRegion>Gwangju</wicri:noRegion></affiliation></author><author><name sortKey="Ryu, Hwa Ja" sort="Ryu, Hwa Ja" uniqKey="Ryu H" first="Hwa-Ja" last="Ryu">Hwa-Ja Ryu</name></author><author><name sortKey="Lee, Se Hoon" sort="Lee, Se Hoon" uniqKey="Lee S" first="Se-Hoon" last="Lee">Se-Hoon Lee</name></author><author><name sortKey="Hwang, Soonwook" sort="Hwang, Soonwook" uniqKey="Hwang S" first="Soonwook" last="Hwang">Soonwook Hwang</name></author><author><name sortKey="Breton, Vincent" sort="Breton, Vincent" uniqKey="Breton V" first="Vincent" last="Breton">Vincent Breton</name></author><author><name sortKey="Rhee, Joon Haeng" sort="Rhee, Joon Haeng" uniqKey="Rhee J" first="Joon Haeng" last="Rhee">Joon Haeng Rhee</name></author><author><name sortKey="Kim, Doman" sort="Kim, Doman" uniqKey="Kim D" first="Doman" last="Kim">Doman Kim</name></author></analytic><series><title level="j">Bioorganic & medicinal chemistry letters</title><idno type="eISSN">1464-3405</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Binding, Competitive</term><term>Computer Simulation</term><term>Cysteine Endopeptidases (genetics)</term><term>Drug Delivery Systems</term><term>Enzyme Activation (drug effects)</term><term>Escherichia coli (genetics)</term><term>Escherichia coli (metabolism)</term><term>Inhibitory Concentration 50</term><term>Models, Molecular</term><term>Molecular Structure</term><term>Protease Inhibitors (chemistry)</term><term>Protease Inhibitors (pharmacology)</term><term>Recombinant Proteins (chemistry)</term><term>Recombinant Proteins (genetics)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (enzymology)</term><term>Small Molecule Libraries</term><term>Viral Proteins (antagonists & inhibitors)</term><term>Viral Proteins (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation enzymatique ()</term><term>Bibliothèques de petites molécules</term><term>Concentration inhibitrice 50</term><term>Cysteine endopeptidases (génétique)</term><term>Escherichia coli (génétique)</term><term>Escherichia coli (métabolisme)</term><term>Fixation compétitive</term><term>Inhibiteurs de protéases ()</term><term>Inhibiteurs de protéases (pharmacologie)</term><term>Modèles moléculaires</term><term>Protéines recombinantes ()</term><term>Protéines recombinantes (génétique)</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Protéines virales (génétique)</term><term>Simulation numérique</term><term>Structure moléculaire</term><term>Systèmes de délivrance de médicaments</term><term>Virus du SRAS ()</term><term>Virus du SRAS (enzymologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Protease Inhibitors</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Recombinant Proteins</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Enzyme Activation</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Cysteine endopeptidases</term><term>Escherichia coli</term><term>Protéines recombinantes</term><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Escherichia coli</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Binding, Competitive</term><term>Computer Simulation</term><term>Drug Delivery Systems</term><term>Inhibitory Concentration 50</term><term>Models, Molecular</term><term>Molecular Structure</term><term>Small Molecule Libraries</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Activation enzymatique</term><term>Bibliothèques de petites molécules</term><term>Concentration inhibitrice 50</term><term>Fixation compétitive</term><term>Inhibiteurs de protéases</term><term>Modèles moléculaires</term><term>Protéines recombinantes</term><term>Simulation numérique</term><term>Structure moléculaire</term><term>Systèmes de délivrance de médicaments</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The 3C-like protease (3CL(pro)) of severe acute respiratory syndrome associated coronavirus (SARS-CoV) is vital for SARS-CoV replication and is a promising drug target. Structure based virtual screening of 308307 chemical compounds was performed using the computation tool Autodock 3.0.5 on a WISDOM Production Environment. The top 1468 ranked compounds with free binding energy ranging from -14.0 to -17.09 kcal mol(-1) were selected to check the hydrogen bond interaction with amino acid residues in the active site of 3CL(pro). Fifty-three compounds from 35 main groups were tested in an in vitro assay for inhibition of 3CL(pro) expressed by Escherichia coli. Seven of the 53 compounds were selected; their IC(50) ranged from 38.57±2.41 to 101.38±3.27 μM. Two strong 3CL(pro) inhibitors were further identified as competitive inhibitors of 3CL(pro) with K(i) values of 9.11±1.6 and 9.93±0.44 μM. Hydrophobic and hydrogen bond interactions of compound with amino acid residues in the active site of 3CL(pro) were also identified.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21470860</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1464-3405</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>10</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Bioorganic & medicinal chemistry letters</Title><ISOAbbreviation>Bioorg. Med. Chem. Lett.</ISOAbbreviation></Journal><ArticleTitle>Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.</ArticleTitle><Pagination><MedlinePgn>3088-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bmcl.2011.03.034</ELocationID><Abstract><AbstractText>The 3C-like protease (3CL(pro)) of severe acute respiratory syndrome associated coronavirus (SARS-CoV) is vital for SARS-CoV replication and is a promising drug target. Structure based virtual screening of 308307 chemical compounds was performed using the computation tool Autodock 3.0.5 on a WISDOM Production Environment. The top 1468 ranked compounds with free binding energy ranging from -14.0 to -17.09 kcal mol(-1) were selected to check the hydrogen bond interaction with amino acid residues in the active site of 3CL(pro). Fifty-three compounds from 35 main groups were tested in an in vitro assay for inhibition of 3CL(pro) expressed by Escherichia coli. Seven of the 53 compounds were selected; their IC(50) ranged from 38.57±2.41 to 101.38±3.27 μM. Two strong 3CL(pro) inhibitors were further identified as competitive inhibitors of 3CL(pro) with K(i) values of 9.11±1.6 and 9.93±0.44 μM. Hydrophobic and hydrogen bond interactions of compound with amino acid residues in the active site of 3CL(pro) were also identified.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Thi Thanh Hanh</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Hwa-Ja</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Se-Hoon</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Soonwook</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Breton</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Joon Haeng</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doman</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioorg Med Chem Lett</MedlineTA><NlmUniqueID>9107377</NlmUniqueID><ISSNLinking>0960-894X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.28</RegistryNumber><NameOfSubstance UI="C052731">3C proteases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="Y">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="Y">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="Y">Protease Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="Y">Small Molecule Libraries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>02</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21470860</ArticleId><ArticleId IdType="pii">S0960-894X(11)00353-2</ArticleId><ArticleId IdType="doi">10.1016/j.bmcl.2011.03.034</ArticleId><ArticleId IdType="pmc">PMC7126700</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Med Chem. 2008;15(1):37-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18220761</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biopolymers. 1996 Mar;38(3):305-20</Citation><ArticleIdList><ArticleId IdType="pubmed">8906967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochemistry. 2004 May 4;43(17):4906-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15109248</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Chem Inf Model. 2007 Sep-Oct;47(5):1818-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17727268</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-2315</Citation><ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Pharm Des. 2004;10(9):1011-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15078130</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Protein Eng. 1995 Feb;8(2):127-34</Citation><ArticleIdList><ArticleId IdType="pubmed">7630882</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):63-73</Citation><ArticleIdList><ArticleId IdType="pubmed">17397958</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem. 2008 Apr 1;16(7):4138-49</Citation><ArticleIdList><ArticleId IdType="pubmed">18343121</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Comput Chem. 2004 Oct;25(13):1605-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2005 Feb;65(2):69-78</Citation><ArticleIdList><ArticleId IdType="pubmed">15708633</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 2000 Jan 1;28(1):235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10592235</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2009 Mar 20;284(12):7646-55</Citation><ArticleIdList><ArticleId IdType="pubmed">19144641</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Corée du Sud</li></country></list><tree><noCountry><name sortKey="Breton, Vincent" sort="Breton, Vincent" uniqKey="Breton V" first="Vincent" last="Breton">Vincent Breton</name><name sortKey="Hwang, Soonwook" sort="Hwang, Soonwook" uniqKey="Hwang S" first="Soonwook" last="Hwang">Soonwook Hwang</name><name sortKey="Kim, Doman" sort="Kim, Doman" uniqKey="Kim D" first="Doman" last="Kim">Doman Kim</name><name sortKey="Lee, Se Hoon" sort="Lee, Se Hoon" uniqKey="Lee S" first="Se-Hoon" last="Lee">Se-Hoon Lee</name><name sortKey="Rhee, Joon Haeng" sort="Rhee, Joon Haeng" uniqKey="Rhee J" first="Joon Haeng" last="Rhee">Joon Haeng Rhee</name><name sortKey="Ryu, Hwa Ja" sort="Ryu, Hwa Ja" uniqKey="Ryu H" first="Hwa-Ja" last="Ryu">Hwa-Ja Ryu</name></noCountry><country name="Corée du Sud"><noRegion><name sortKey="Nguyen, Thi Thanh Hanh" sort="Nguyen, Thi Thanh Hanh" uniqKey="Nguyen T" first="Thi Thanh Hanh" last="Nguyen">Thi Thanh Hanh Nguyen</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001404 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001404 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:21470860
|texte= Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:21470860" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |